LearnGlossaryMarketStocksSuperinvestorsSign in

KRRO

Korro Bio, Inc.

Healthcare · $97M market cap

Verdict

We can't put a fair value on KRRO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-52.8% a year✗
Sales growth-26.0% a year✗
Free cash flow growth—?
Return on invested capital-56.1%✗

Follow KRRO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: no open-market purchases and 2 sales worth $99K. Why purchases matter

Sales

Dolan Oliver

Senior Vice President, Finance · 2026-09-09

Sold

$82

Dolan Oliver

Senior Vice President, Finance · 2026-09-08

Sold

$99K

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works